As the developing heart grows and the chamber walls thicken, passive diffusion of oxygen and nutrients is replaced by a vascular plexus which remodels and expands to form a mature coronary vascular system. The coronary arteries and veins ensure the continued development of the heart and facilitate cardiac output with progression towards birth. Many aspects of coronary vessel development are surprisingly not well understood and recently there has been much debate surrounding both the developmental origin and tissue contribution of cardiovascular cells alongside the specific signals that determine their fate and function. What is clear is that an understanding of the cellular and molecular cues to vascularize the heart of the embryo has significant implications for adult heart disease and regeneration, as we move towards targeted cell-based therapies for neovascularization and coronary bypass engraftment. This review will focus on the proposed cellular origins for the coronary endothelium with due consideration to the pro-epicardial organ/epicardium, sinus venosus and endocardium as potential sources, and we will explore the outstanding questions and technical limitations with respect to accurate labelling and lineage tracing of the developing coronaries. We will briefly document canonical vascular signalling that induces vessels in the heart alongside a focus on the potential for developmental reprogramming and putative mechanisms underpinning venous vs. arterial cell fate. Finally, we will extrapolate directly from development to address adult maintenance of the coronaries, vascular homeostasis and remodelling in response to pathology, aligned with the potential for revascularizing the injured adult heart.
Introduction
The development of the coronary vessels, and subsequent attachment of the main coronaries to the closed vascular system of the embryo, is fundamental for continued foetal growth and survival. Traditionally, coronary vessels were thought to have a unique derivation from mesothelial cells arising from the proepicardium or proepicardial organ (PEO) and yet retain a high level of functional and molecular similarity to the systemic vasculature. Proepicardial cells are transferred to the heart by complex signalling and epithelial-mesenchymal transition (EMT) to form the epicardium and give rise to endothelial cells (ECs), smooth muscle cells, and cardiac fibroblasts (reviewed in Smart et al. 1 ). Endothelial cells derived from the epicardium form a vascular plexus by combined vasculogenesis and angiogenesis to remodel and expand the vascular network, which subsequently attaches to the aorta and recruits epicardially derived mesenchyme to become vascular smooth muscle cells (VSMCs) through arteriogenesis. Interest in coronary vessel formation stems not only from the fact that it is essential for embryonic survival, but also because there is the distinct possibility of developmental studies uncovering cellular and molecular cues towards neovascular repair of the diseased adult heart.
Cellular origins of the coronary vasculature
Despite the fact that the development of the vessels of the heart has been a subject of relatively intense study for more than a century, there is still ongoing debate regarding the cellular origin and tissue sources for the coronary vasculature.
The PEO/epicardium: a historical perspective
Early anatomical observations documented that the coronary vessels simply bud off from the aorta but these were challenged by studies in which coronary arteries were observed to grow into the aorta. 2 More recent retroviral tagging, adenoviral cell lineage tracing, and quailchick chimera studies have proposed the PEO as a source of the coronary vasculature. 3 -5 The PEO is a transient extracardiac mesothelial cell population situated between the sinus venosus and the liver in chick and on the surface of the septum transversum in mouse. 6 PEO cells migrate to the developing heart and envelope the surface to give rise to the epicardium. A subpopulation of epicardium-derived progenitor cells delaminate from this primitive epithelium and undergo EMT to generate a population of mesenchymal cells which migrate into the underlying myocardium and give rise to VSMCs, pericytes, fibroblasts, and cardiomyocytes. 3,7 -9 That the coronary ECs are also EPDC-derived is controversial. It is widely accepted that not all vascular ECs are contributed by the epicardium, 10 and an increasing number of studies now argue that very few, if any, coronary ECs are PEO -epicardium-derived. In chick -quail chimera studies with anti-endothelial immunohistochemistry, prospective coronary ECs were mapped back to the liver sinusoids extending into the sinus venosus lumen via the PEO 11 with the liver subsequently proposed to be a primary source of endothelial progenitor cells (EPCs). 12 In mouse, lineage tracing and fate mapping of epicardium derived cells (EPDCs) during development have either failed to identify epicardium-derived ECs 8 or observed that the epicardium gives rise to only a few isolated ECs. 9 
A sinus venosus and endocardium contribution?
More recently, in mouse, coronary vessels have been shown to arise from angiogenic sprouts of the sinus venosus, the endothelial-lined cavity at the inflow region of the embryonic heart. 13 The sinus venosus was identified as a site for the earliest appearance of vessels in the heart in classical embryological studies in dogfish 14 and, in mouse, a connection of the undifferentiated coronary vascular network to the sinus venosus was also previously demonstrated. 15 However, there was no historical insight into a sinus venosus origin for coronary artery ECs until the recent study by Red-Horse et al. 13 Here, the authors fate mapped lacZ+ ECs via an ephrinB2-LacZ reporter to determine that coronary sprouts were continuous with the sinus venosus and did not arise from the PEO or other vasculogenic sources. This was complimented by organ culture and tissue recombination to demonstrate EC outgrowth restricted to sinus venosus and atrium, which in turn was dependent upon unknown signals from the ventricle and epicardium, and clonal analysis with an inducible VE-cadherin-CreER transgene to map the origin and fate of coronary endothelial progenitors in vivo. The clonal analysis, via an early (E7.5) induction of VE-cadherin-CreER, suggested that coronary artery progenitors arise from differentiated veins and this was confirmed by documenting a switch in molecular signature from a venous (EphB4+) to arterial (ephrinB2+) identity within the coronary sprouts as they emerged from the sinus venosus.
What the clonal analysis also revealed 13 was a secondary source of coronary ECs from the endocardium. In the mouse, endocardial cells are among the earliest ECs that differentiate from Vegfr-2-positive (Vegfr-2+) multipotent progenitors within the heart field. 16 They form an endocardial tube by de novo growth or vasculogenesis and later become the inner epithelial lining or endocardium of the heart, 17 subsequently contributing to the formation of the cardiac valves and membranous septa by endocardial-to-mesenchymal transformation. 18 Relative to the endocardial ECs, coronary ECs arise later in the developing heart which establishes a potential for contribution of the former to the latter population, although, to date, this has again proven somewhat controversial. That the primitive vascular bed might arise as a continuation of the endocardium was first described in the developing rat heart 19 and subsequently in mouse, where the first vessels of the heart were described as appearing by the invagination of the endocardium. 6 In contrast, retroviral tracing in chick revealed
ECs of the coronary vessels to have a different clonal origin than ECs of the endocardium. 7 Red-Horse et al. 13 were the first to genetically trace and clonally map an endocardial origin for coronary ECs, albeit a relatively minor contribution with the tools they employed and described a process of endocardial budding to form endothelial blood islands which they hypothesized might join the sinus venosusderived plexus. A more autonomous and potentially more extensive contribution of endocardial ECs to the coronary vasculature is yet to be determined, but since endocardial cells closely resemble endothelial precursor cells in terms of their molecular profile, unequivocal lineage tracing and chimera analyses are somewhat confounded. 12 
Reconciling a common source for coronary ECs
So what is the current state of play and what if any is the consensus on the origins of the coronary vasculature? In attempting to reconcile all of the above, it is important to take account of species differences, with a focus on avian vs. rodent as the most studied vertebrate models. It would appear that there are two schools of thought derived from avian studies. The first advocates that the PEO/epicardium contributes cells to the developing coronary vessels, 5 although the PEO is not the sole source 20 and indeed it is apparent that other cell types may participate in the building of the coronary tree. The second focuses on the 'other cell types' and in particular proposes a non-PEO source favouring the liver sinusoids and sinus venosus. 11 In this respect, the quail-to-chick and/or retroviral techniques used to tag the developmental fate of avian PEO or sinus venosus cells cannot guarantee that all the coronary progenitors are properly labelled and, therefore, not only is it difficult to encompass different contributions from different sources in a single experiment, but it is equally difficult to make an accurate quantitative assessment between experiments for cellular contribution in coronary morphogenesis. In rodents, and in particular mice, where genetic lineage tracing and fate mapping tools are available, there has been a recent movement away from a single PEO/epicardium source for coronary ECs. New insight has informed on contributions from dedifferentiation of the sinus venosus endothelium at least giving rise to the coronary arteries. This of course begs the question as to the origin of the ECs that comprise the early coronary veins and in particular the endothelial lining of the sinus venosus? Moreover, the endocardium has been implicated as a source of ECs that may further contribute to the developing coronary plexus, and indeed, the precise extent of endocardial contribution remains unknown. It would appear that regardless of source, the coronary ECs in mammals represent a specified lineage within the vasculature arising in part from a subpopulation of venous ECs at defined stages in development. Furthermore, as far as the PEO and sinus venosus are concerned, their adjacent location at the inflow region of the developing mouse heart and proximal to the liver primordium ( Figure 1A ) means that it is extremely difficult with the current tools available (specific Cre-expressing lineage mouse lines) to unequivocally rule out common progenitor pools. Equally, we are unable to discern early contribution of prospective liver sinusoid progenitors directly to the sinus venosus, or via the PEO which in turn contribute to the sinus venosus and ultimately the coronary vasculature ( Figure 1B) . In the principal cell lineage tracing adopted by Red-Horse et al., 13 namely the crossing of VE-Cadherin-CreER;ROSA26 animals, while they could rule in the sinus venosus source for coronary ECs, the selective expression of Cre under the control of VE cadherin and the relative timing of induction meant that they were unable to rule out the possibility that ECs, either from a distinct source (PEO, endocardium) or arising as earlier progenitors elsewhere and migrating to the sinus venosus, may contribute to the building of the coronary tree.
Confounding avian -rodent species differences
Differences between the chick-quail and mouse-rat studies may reflect not only the outcome of different technologies applied, retroviral tracing in chick vs. genetic fate mapping in mouse, but also may be an indictment on differences in the formation and patterning of the vascular beds in avian compared with rodent hearts. A potentially unifying theme, however, is that most, if not all, of the reports found in the literature support the concept that the avian and mammalian PEO contains some sort of vascular progenitor cell type or (haem-) angioblast. The specific embryological origin of this angioblast population and whether it contributes as a whole or in part to the sinus venosus ECs, or the endocardium, as an intermediate stage prior to coronary vascularization ( Figure 1B ), remain to be determined and are still open to speculation.
Cre-lox technology to dissect out coronary origin
When addressing the question of origin, it is imperative to consider the possible vagaries of fate mapping alongside the pitfalls of using the favoured Cre-lox system in mouse, as weighted against speciesspecific differences and possible heterogeneity in the origins of the vascular lineages. In addition, there is a requirement to establish criteria for optimal assessment of the progressive contribution of coronary vascular cells from the earliest angioblast cell (if such a cell exists?) to the differentiated arterial EC. From the outset, we require a wider range of markers of the prospective tissue sources for coronary cells, both to distinguish between alternate origins ( Figure 1 ) and to facilitate fate mapping at the earliest time points, thus addressing the question of a common progenitor pool. In this regard, the so-called natural history of genes we might adopt as tools for fate mapping becomes important. Within a specific source, we require finer mapping to identify progenitors which may have overlapping and/or distinct expression profiles for specific markers and to identify a more comprehensive gene-set with which to speak to the entire heterogeneity of cells within a source and to resolve the complete fate map.
In the case of the PEO, genetic markers which are expressed at an early stage in PEO development and in cells entirely or partially distinct from previously described Tbx18-positive and Wt1-positive populations are required to trace distinct subcompartments. One approach towards identifying novel factors around the model of a venous origin might be to build on the transcriptional code for systemic vascular ECs defined by a composite cis-acting element, the FOX:ETS motif. 21 Thus, a suitable screen for coronary EC-specific enhancers, which might act in concert with the FOX:ETS/ets cluster, could be utilized to establish reporter lines and to identify trans-acting factor(s) for use in Cre-lox lineage tracing. Subsequently, selection of a specific gene locus and/or enhancer region to drive Cre should be set against high-resolution in situ expression for the gene of interest to ensure that there is no possibility of Cre being expressed within the descendant ECs or in more than one putative source for ECs to cloud interpretation on origin. Ideally, in any single study, multiple Cre lines should be employed to identify potentially distinct sources for ECs and one must consider the efficacy of the Cre. With variable efficacy comes differential sensitivity of individual alleles to Cre-mediated recombination which limits the utility of reporter alleles. 22 This has important implications for interpreting
Cre fate mapping experiments with the potential for alternate reporters defining narrower or broader daughter cell domains. Recently, the widely used R26R reporter, based on the Rosa-26 locus, was shown to be less susceptible to Cre in studies tracking Isl1-and Nkx2.5-expressing progenitors in cardiogenesis than an alternative Gata4-flap reporter, providing unique insight into the contribution of Isl1 descendants to both primary and secondary heart fields and Nkx2.5 descendants to the coronary endothelium and smooth muscle. 23 A further generic challenge with Cre-lox technology is the issue of potential toxicology of Cre recombinase arising from recombination at cryptic or pseudo-loxP sites within the genome hindering the cellular DNA repair machinery and ultimately resulting in apoptosis. 22 As a minimum requirement, the Cre drivers should be inducible to avoid issues with (i) spurious activation of Cre due to prior expression in founder populations, (ii) detecting descendants of rare cells that have activated Cre at an earlier time point, and (iii) ectopic expression of Cre in ECs that does not reflect lineage contribution. Finally, the timing of induction needs to be early enough so as to trace progenitors which may contribute transiently to intermediate 'sources' (e.g. a potential PEO/epicardium contribution to the endocardium and sinus venosus) en route to the coronaries (Figure 1 ).
Classical embryology, clonal and transplant analyses
Even if safeguards are imposed against a misinterpretation of the Cre-lox labelling, evidence that the coronary cells are indeed the linear descendents of cells that were expressing the gene (employed to drive Cre) in the specific source at earlier stages must be provided to claim lineage tracing and fate mapping. Here, Cre-lox can be complimented by other analyses. Returning to more classical embryology, in vivo vital dye (DiI) injection and physical labelling of progenitors in conjunction with whole-embryo culture remains a valid approach and has been used successfully elsewhere in both chick and mouse. 24 Organ culture and tissue recombination, as previously described, 13 is potentially informative regarding a single origin but is restricted against the breadth of potential sources in vivo as it is not possible to ascertain whether all coronary ECs might arise from the specific cultured tissues. Additional insight can arise from the culture of neighbouring tissues where there may be a requirement for secreted signals from one tissue to induce coronary EC outgrowth and remodelling in another and, in such cases, co-culture may facilitate the identification of signals by mass spectrometry or via a candidate approach. 25 Clonal analysis is a potentially powerful tool to map origin and determine proliferation, outgrowth and fate of the coronary progenitors in vivo. This analysis is, however, open to over-interpretation and dependent upon inducible genetic labelling which can be biased from the outset, so as not to be inclusive of all possible sources. 13 Here, the solution might be to perform a time course of inductions to potentially encompass all clones of vascular progenitors. A further issue with clonal analysis is the documenting of a rare genetic recombination event and the tracking of a discrete number of clones on the assumption that this stochastically reflects the entire lineage. In the case of venous-to-arterial reprogramming, the frequency of arterial EC clones arising from venous ECs was in fact quite low (around 1-3%) 13 which could be interpreted to the effect that venous ECs are not the primary source of coronary arteries, leaving open the identity of the arterial antecedents. A further complementary approach is engraftment, such that labelled endothelial progenitors are transplanted into the embryo to determine lineage potential and an EC fate within the developing heart. This is, however, compounded by technical difficulties regarding the isolation and transplantation procedure, propensity for phenotypic drift during culture, and mode of delivery. Further caveats include subsequent graft survival alongside a reduced exposure to the appropriate in vivo signals which may be critical to determine EC fate.
Defined sources of coronary vascular smooth muscle
In stark contrast to the coronary endothelium, the VSMCs have fairly well-defined origins, dependent on location within the developing heart and function (reviewed in Luttun and Carmeliet 26 ). Simply put, VSMCs of the proximal and major anterior coronary arteries arise from the neural crest and the rest derive from the PEO and epicardium. 27 In contrast, coronary vein VSMCs arise from an atrial cardiomyocyte origin. 28 
Developmental programming of vessels in the heart
In keeping with the prevailing dogma of a PEO/epicardium origin for the coronary vasculature, there has been considerable focus on the communication of signals between the PEO/epicardium, subepicardial mesenchyme, and myocardium. These signals regulate coronary development and myocardial growth and are mediated in part by secreted growth factors which originate from the epicardium and EPDCs or from cardiomyocytes and which sit at the top of hierarchical signalling pathways to act in an autocrine or paracrine fashion. Although some growth factors have been implicated in the formation of vascular beds elsewhere during development, the pathways they mediate within the heart are largely distinct from those that govern vasculogenesis in the rest of the embryo (reviewed in Olivey and Svensson 29 ) . What is evident is that reciprocal signalling between lineages such as the PEO/epicardium, endocardium, and myocardium ensures developmental coupling of coronary vessels with that of myocardial growth (reviewed in Bhattacharya et al.
30
). Suffice to say that TGF, FGF, VEGF, PDGF, BMP, Wnt/b-catenin and retinoic acid pathways have all been implicated in epicardial-myocardial or myocardial-epicardial signalling principally in support of PEO/epicardial EMT, outgrowth, protrusion and adhesion of EPDCs plus the induction and remodelling of the coronary plexus. For detailed accounts of growth factor function and downstream signalling in coronary development, refer to reviews elsewhere 1,26,29 -31 and references therein.
Signalling to specify arteriovenous identity?
When considering the molecular control of vessel formation in the developing heart, a key question is what are the signals which specify venous vs. arterial identity? Physical forces such as blood flow have been implicated in the regulation of EC fate. Coronary veins develop before arteries and the latter have been considered simplistically as a by-product of the recruitment of a medial layer of VSMCs in response to pressure increase and blood flow alteration after connection to the aorta. 26 Hence, direct stretch and sheer forces acting on the endothelium or VSMC differentiation and subsequent smooth muscle paracrine signalling may instruct coronary ECs to adopt an arterial fate, or at later stages ensure appropriate arterial EC differentiation and functional maturation. A robust argument against altered haemodynamics as determinants of arterial EC fate arises in the study proclaiming coronary artery formation by developmental reprogramming of venous cells. 13 In the model proposed, sprouting sinus venosus ECs are initially differentiated with a venous identity characterized by Ephb4 expression and other venous markers such as Vegfr3, Np2, Aplnr and COUP-TFII but, as angiogenesis extends beyond the sinus venosus, those vessels which invade the myocardium begin to express ephrinB2 and other arterial markers such as Dll4, Hey1, Notch4 and Depp. The timing of the initial down-regulation of Ephb4 as the first stage in venous reprogramming towards arterial fate is E11.5 in the mouse which significantly precedes arteriogenesis and the connection of the vascular network to the aorta. This suggests that arterial specification is a preprogrammed spatial event occurring in response to either positive induction via signals from the myocardium/endocardium or reduced exposure to inhibitory signals from the PEO/epicardium and sinus venosus. However, this does not rule out a role for haemodynamics in ensuring subsequent assembly into mature coronary arteries. The identity of flow/pressure-dependent signals is currently unknown but, outside of the coronaries, molecular readouts have been elegantly defined in response to haemodynamic changes in the developing branchial arch arteries (BAAs). Blood flow in the left sixth BAA is sufficient to stimulate PDGFR and VEGFR2 signalling to maintain arterial structure whereas, with decreased blood flow in the right sixth BAA, the consequence is arterial regression. 32 
Coronary artery induction by Notch
The molecular profile of coronary arterial ECs, which includes Dll4, Hey1 and Notch4, implicates Notch signalling as a potential inducer of arterial cell fate. Delta-Notch plays a central role in vertebrate organogenesis per se and regulates multiple processes during cardiac development, where it functions both cell autonomously and non-cell autonomously pointing to a role as a signal coordinator during cardiogenesis (reviewed in MacGrogan et al.
33
). Notch signalling within the myocardium is known to be important for cardiomyocyte differentiation, ventricular trabeculation and outflow tract development, and there is also a critical role for Notch in the endocardium, such that Notch1, via interplay with myocardial Bmp2, restricts endocardial EMT to a valve-forming field. 34 In avian coronary vasculogenesis, active Notch1 (the Notch1 intracellular domain; N1ICD) is present within the mesothelial cells of the PEO, the mesenchymal cells of the epicardium and in the ECs within the nascent vessel plexus at the atrioventricular junction, suggesting that Notch1 is important in the chick for epicardial EMT and coronary progenitor cell differentiation. 35 In mice, which lack Notch1 or have a combined loss of the Notch targets, Hey1 and Hey2, the mutant phenotype is characterized by cardiac defects and coronaries which fail to express arterial markers, including ephrinB2. This suggests that Hey1 and Hey2 are essential transducers of Notch signals and may mediate arterial fate decision. 36 Notch also functions at later stages in coronary maturation and is up-regulated in response to VEGF signalling to establish a Notch/ephrinB2 cascade and ensure coronary arteriogenesis. 15 
Determinants of venous identity and reprogramming?
Although Notch signalling may define coronary arterial ECs, we have no current insight into the determinants of coronary venous fate or the signals which instigate venous reprogramming in the process of coronary artery formation. During remodelling of the systemic primary capillary plexus in the early embryo, arteriovenous differentiation involves suppression of Notch signalling in venous ECs by the nuclear orphan receptor COUP-TFII which permits expression of the venous marker EphB4. 37 This seems to indicate a default arterial EC fate in systemic vasculogenesis which requires active suppression. It is not known whether this is the case in early coronary vessel development but is somewhat unlikely, given the recent precedent for venous EC differentiation as the earlier event within the sinus venosus, followed by subsequent reprogramming towards an arterial fate. 13 In terms of venous reprogramming, although again untested in terms of the coronary vasculature, during systemic vasculogenesis, it is clear that the EphB4 receptor tyrosine kinase and its plasma membrane-spanning ligand, ephrinB2, demarcate venous and arterial domains, respectively. 38 Moreover, a number of studies of EphB4-and ephrinB2-null mice have revealed roles for forward and reverse EphB4 -ephrinB2 signalling in vascular morphogenesis. 38 -40 This establishes a molecular basis for bidirectional programming of venous -arterial EC fate; however, the exact function and mode of action of bidirectional EphB4 -ephrinB2 signalling remains unknown (reviewed in Adams and Alitalo 41 ). An understanding of the molecular signals which instruct dedifferentiation and reprogramming of coronary vessels is an obvious priority in terms of not only identifying pathways underlying coronary development but towards the induction of new vessels in adult cardiac repair.
Adult maintenance and pathological remodelling 4.1 Maturation of the post-natal coronaries
The coronary vasculature continues to mature post-natally, growing significantly in the first 2 weeks after birth to keep pace with 80% increase in cardiac mass. 42 Indeed, a 2.8-fold increase in capillary growth occurs during the first 5 days of post-natal life, predominantly by intussusceptive growth, i.e. splitting of pre-existing capillaries. 43 FGFs play a key role in perinatal arterial development, such that precocious expression of FGF-2 following retroviral epicardial injection in chicks causes abnormal branching of coronary vessels, 44 whereas
anti-FGF-2-neutralizing antibodies, administered between 5 and 12 days after birth, inhibited arteriolar growth. 42 Coronary artery remodelling is necessary to establish an effective hierarchy within the arterial tree. Initiation of blood flow through the coronary system provides the stimulus for remodelling the main arteries, inducing EC proliferation and up-regulating VEGF, integrin aVb3, PECAM-1 and VE-cadherin 45 to increase vessel diameter. Anti-VEGF neutralizing antibody disturbed the normal arteriolar hierarchy, implying that although FGF-2 appears to direct arteriolar growth, its interaction with VEGF serves to establish a normal hierarchy of the coronary tree, limiting growth of terminal arterioles and facilitating growth and remodelling of upstream arterioles. 42 
Homeostatic maintenance and turnover of adult endothelium
Once the mature coronary architecture is established, appropriate angiogenic signalling is required thereafter for its maintenance.
Renewal of vascular cells, as and when required, is facilitated by progenitor cell populations, derived either from bone marrow or resident within the vessels or myocardium 46 (further reviewed in Hibbert et al. 47 ). Even the healthy endothelium is turned over approximately every 3 years 48 and the cellular source for its renewal may not necessarily derive from the same embryonic lineage as the original. The notion that vessels in the adult are derived only by angiogenesis, and not by vasculogenesis as in the embryo, has now been superseded following the acceptance that circulating EPCs, derived from bone marrow, represent at least one source of vascular progenitors that actively contribute to new vessel growth in the adult. Analogous in many respects to the embryonic angioblast, EPCs are mobilized, when required, from the bone marrow and incorporate into new or injured vessels where they develop into mature ECs during the processes of re-endothelialization and neovascularization (reviewed in Smart and Riley
49
). The precise molecular definition of EPCs across animal models, and including humans, is somewhat controversial, although there is a consensus that their beneficial effects may also be mediated, in part, through paracrine secretion of angiogenic factors (Figure 2) .
ECs ordinarily reside in a non-proliferative state throughout their average lifespan of between 1 and 3 years. 50 Despite their quiescent appearance, ECs are highly metabolically active, playing key roles in controlling vasomotor tone, blood cell trafficking, haemostatic balance, permeability and immunity. The endothelium exerts effects on both the surrounding VSMCs and blood cells to coordinately regulate tissue blood supply balancing vasodilation with vasoconstriction, VSMC differentiation, inflammatory responses, maintenance of blood fluidity and prevention of bleeding. 51 A critical balance between endothelium-derived paracrine factors appears to regulate vascular homeostasis, and similarly, VSMCs rarely proliferate under normal physiological conditions, rather they remain in a differentiated contractile state.
Consequences of endothelial dysfunction in vascular disease
In disease states leading to deterioration in endothelial function, a proportion of VSMCs adopt a dedifferentiated, proliferative state leading to pathological changes in the vascular walls, including a loss of cytoskeletal markers and their ability to respond to contractile stimuli. If the processes of endothelial homeostasis and repair both fail, endothelial damage ultimately leads to arterial stiffness (arteriosclerosis) and lipid accumulation (atherosclerosis). Atherosclerosis is not simply an inevitable degenerative consequence of ageing, rather a form of chronic inflammation. 52 The inflammatory cytokines interleukin-1, tumour necrosis factor-a and g-interferon transform ECs to an active state. Activated ECs express leukocyte adhesion molecules and produce tissue factor to create a procoagulant environment which is augmented by accompanying vasoconstriction through an up-regulation of endothelin-1 in a setting of diminished nitric oxide (NO) production. This in turn is permissive for neointimal proliferation, due to loss of the usual VSMC growth inhibitory factors, and vascular occlusion. Coronary artery occlusion may not always lead to infarction since in two-thirds of patients with CAD, collateral arteries develop from pre-existent interconnecting arterioles, by proliferation of VSMCs and ECs, to bypass the stenosis. 53 Fluid shear stress (FSS) is the primary trigger for collateral growth and increased pulsatile FSS leads to deformation of the endothelium and activation of all NO synthase isoforms. NO production, followed by VEGF secretion, induces monocyte chemoattractant protein-1 synthesis that attracts monocytes and T cells to attach to the endothelium; these produce proteases to digest the internal elastic lamina and extracellular matrix and simultaneously induce a phenotypic change of ECs and VSMCs into the synthetic and proliferative types. Following proliferation, vessels mature via orderly arrangement of the VSMCs in circular layers, establishment of cell-to-cell contacts and synthesis of elastin and collagen to provide scaffold for the larger vessel.
Neovascularization and bypass engraftment
Although the phenomenon of collateral growth has long been recognized, attempts to therapeutically stimulate these processes have lagged behind. Capillaries that form by vasculogenesis, without smooth muscle support, are unstable and regress over time.
Compared with vasculogenesis, arteriogenesis is more complex and has proven more recalcitrant to therapy. Arteriogenesis is not stimulated by the same signals, such as hypoxia, but rather by haemodynamic forces, principally shear stress 54 ; therefore, although single genes or proteins successfully induce coronary angiogenesis, the simultaneous activation of multiple growth factors is seemingly required to stimulate arteriogenesis. 55 Therapeutic methodologies have, therefore, evolved to concomitantly activate several growth factors, for example, by providing a metabolic stimulus, such as the thyroxine analogue 3,5-diiodothyropropionic acid (DITPA). 56 DITPA administration to rats post-MI enhanced levels of VEGF, FGF-2,
Vascularizing the heart Ang-1, and Tie-2, leading to increased arteriolar density and improved left ventricular function. A natural consequence of arterial occlusion and ischaemia is the establishment of a hypoxic environment which has significant effects on the neovascular response. The regulation of angiogenesis by hypoxia depends on a precise balance between positive and negative angiogenic regulatory molecules. Increasing evidence points to the existence of complex feedback networks such that factors generally considered pro-angiogenic, such as HIF-1, additionally activate angiogenic inhibitors including Regulator of G protein signalling 5 (RGS5) 57 and Delta-like ligand 4 (Dll4) 58 downstream of VEGF. The negative feedback regulation of angiogenesis during hypoxia may explain not only the inadequate natural collateral circulation in ischaemic heart disease but also the disappointing and inconsistent results of clinical trials. 59 Consequently, identifying key feedback inhibitors may reveal new targets for angiogenic therapy.
Developmental programming to facilitate cell-based neovascularization
An evolving paradigm in regenerative medicine is that tissue repair in the adult is frequently underpinned by a re-activation of the embryonic programme that created the tissue in the first instance. As such, there is much to gain from understanding the embryonic mechanisms of vasculogenesis (recently reviewed). 1, 49 The possibility of a post-natal contribution from cardiac populations that play a role during embryonic development is provided from studies in zebrafish which suggest that EPDCs are incorporated into the heart not only during regeneration, but also during continuous growth of the adult heart. 60 It remains to be determined whether the mammalian epicardium contributes to coronary homeostasis but, if so, the contribution is likely to be much reduced compared with the fish for at least two reasons. The epicardial contribution in zebrafish may be peculiar to the continued organ growth and hyperplasia which is an adaptive precedent in this species and, moreover, in mammals even in the injury setting, an exogenous stimulus, such as Thymosin b4, is required to fully reinstate embryonic potential to adult EPDCs 61 and enable neovascularization of the ischaemic adult heart. 62 
Adult progenitor cell vascular repair
Recent studies have recognized the ability of a multitude of cardiacand vessel-resident progenitor cell populations to engraft into sites of vascular injury or homeostatic replenishment (reviewed in Figure 2 Cellular maintenance and repair of the post-natal coronary vasculature. Under conditions of vascular homeostasis (maintenance) in the adult heart, circulating EPCs respond to a plethora of growth factor and chemokine signalling to home to the coronaries and replenish ECs. Following arterial occlusion leading to vessel regression and MI, a subepicardial graft of c-kit+ cardiac progenitor cells (CPCs) is able to migrate to the site of vascular injury and differentiate into de novo ECs and VSMCs to establish a 'bypass' of the occlusion and reperfuse the injured myocardium. 67 lad, left anterior descending artery; mi, myocardial infarction; ANG1, angiopoietin 1; EPO, erythropoietin; FGF, fibroblast growth factor; HGF, hepatic growth factor; HIF-1a, hypoxia factor-1a; SDF-1, stromal cell-derived factor-1; VEGF, vascular endothelial growth factor.
Hibbert et al. 47 ). Along similar lines, the discovery that circulating EPCs participate in homeostatic neovascular repair has led to many animal studies (reviewed in Miller-Kasprzak and Jagodzinski
63
) and ultimately clinical trials to enhance EPC mobilization from bone marrow to effect neovascularization, with promising preliminary results. 64, 65 With regard to arteriogenic therapy, EPCs would appear inferior to those progenitor cells that possess a broader differentiation potential that also includes pericytes or smooth muscle cells, given the need for mural cell stabilization of vessels. Smooth muscle progenitor cells were more recently identified in bone marrow, circulating blood and vascular adventitia 66 and may prove more successful for coronary neovascularization. More recently, c-kit+ cardiac progenitor cells were shown to differentiate into ECs and SMCs to form conductive (up to 250 mm) and intermediate-sized coronary arteries together with resistance arterioles and capillaries. These new vessels connected with the primary circulation to more than double myocardial flow following MI and thereby constitutes an example of a 'biological coronary bypass' 67 ( Figure 2 ).
Tissue engineering of vascular grafts
A natural progression from cell-based therapy has been the development of tissue engineering techniques. New vessel formation and improvements in neovascularization have been reported in hindlimb ischaemia using human smooth muscle cell sheets 68 or Matrigel plugs seeded with a combination of human endothelial and cord blood-derived mesenchymal progenitor cells. 69 For coronary angiogenesis, in vitro engineered three-dimensional neonatal cardiomyocyte sheets containing preformed EC networks were transplanted onto infarcted rat hearts, resulting in a significantly elevated capillary density with blood vessels originating from the cardiac patch connecting with host capillaries. 70 
Future perspectives
Our understanding of embryonic and post-natal coronary vasculature development has brought us some way towards developing effective strategies to promote neovascularization in cardiovascular repair. Numerous outstanding questions remain regarding the lineages that contribute the cells of the coronary vasculature, the precise mechanisms that govern vascular cell fate, and the regulation of arteriovenous identity, vessel growth, and maintenance. However, further insight into vascularizing the heart during development should pave the way for significant advances in neovascular therapy.
